Cannabinoid transmission and pain perception

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 447-461

  Martin, Billy R ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; ALPHA ADRENERGIC RECEPTOR; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DEXTRONANTRADOL; DRONABINOL; KAPPA OPIATE RECEPTOR; LEVONANTRADOL; NABITAN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; CANCER PAIN; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; TOOTH PAIN;

EID: 0032459476     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0218     Document Type: Article

References (131)

1. O'Shaughnessy W. B. On the preparation of Indian hemp and ganja. Trans. Med. Phys. Soc. Bombay. 8:1842;421-461.
2. Segal M. Cannabinoids and analgesia. Cannabinoids as Therapeutic Agents. 1986;CRC Press, Boca Raton. p. 105-120.
3. Melzack R. Neurophysiological foundations of pain. Sternbach R. A. The Psychology of Pain. 1986;1-24 Raven Press, New York.
4. Dennis S. G., Melzack R. Comparison between phasic and tonic pain in animals. Bonica J. J. Advances in Pain Research and Therapy. 1979;747-760 Raven Press, New York.
5. Noyes J. R., Baram D. A. Cannabis and analgesia. Compr. Psychiat. 15:1974;531.
6. Petro P. J. Marijuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics. 21:1980;81-85.
7. Grinspoon L., Bakalar J. B. Marihuana: The Forbidden Medicine. 1993;Yale Univ. Press, New Haven.
8. Hill S. Y., Goodwin D. W., Schwin R., Powell B. Marijuana: CNS depressant or excitant. Am. J. Psychiat. 131:1974;313-315.
9. Hill S. Y., Schwin R., Goodwin D. W., Powell B. J. Marijuana and pain. J. Pharmacol. Exp. Ther. 188:1974;415-418.
10. Clark W. C., Janal M. N., Zeidenberg P., Nahas G. G. Effects of moderate and high doses of marihuana on thermal pain: A sensory decision theory analysis. J. Clin. Pharmacol. 21:1981;299S-310S.
11. Clark W. C., Janal M. N., Zeidenberg P., Nahas G. G. Effects of moderate and high doses of marijuana on thermal pain: A sensory decision theory analysis. J. Clin. Pharmacol. 21:1981;299S-310S.
12. 9. Braude M. C., Szara S. The Pharmacology of Marihuana. 1976;763-776 Raven Press, New York.
13. 9. J. Clin. Pharmacol. 15:1975;139-143.
14. 9. Clin. Pharmacol. Ther. 18:1975;84-89.
15. 9. Pharmacology. 13:1975;502-512.
16. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: Psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21:1977;26-33.
17. Jochimsen P. R., Lawton R. L., VerSteeg K., Noyes J. R. Effect of benzopyranoperidine, a Δ-9-THC congener, on pain. Clin. Pharmacol. Ther. 24:1978;223-227.
18. Staquet M., Gantt C., Machin B. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin. Pharmacol. Ther. 23:1978;397-401.
19. Jain A. K., Ryan J. E., McMahan F. G., Smith G. Evaluation of intra-muscular levonantradol in acute post-operative pain. J. Clin. Pharmacol. 21:1981;3205-3265.
20. Harris L. S. General and behavioral pharmacology. Pharmacol. Rev. 23:1971;285-294.
21. Davies O. L., Raventós J., Walpole A. L. A method for the evaluations of analgesic activity using rats. Br. J. Pharmacol. 1:1946;255-264.
22. 9. J. Pharm. Pharmacol. 25:1973;344.
23. 9. Harvey D. J. Marihuana '84: Proceedings of the Oxford Symposium on Cannabis. 1985;685-692 IRL Press, Oxford.
24. Little P. J., Compton D. R., Johnson M. R., Melvin L. S., Martin B. R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1988;1046-1051.
25. 2. Brain Res. 559:1991;309-314.
26. 9. J. Pharmacol. Exp. Ther. 268:1993;1381-1387.
27. 99. Neuropharmacology. 17:1978;137-144.
28. Lichtman A. H., Cook S. A., Martin B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
29. Herzberg U., Eliav E., Bennett G. J., Kopin I. J. The analgesic effects ofR. Neurol. Lett. 221:1997;157-160.
30. Smith F. L., Fujimori K., Lowe J., Welch S. P. Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in non-arthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;1-9.
31. Razdan R. K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75-149.
32. Dewey W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
33. Martin B. R., Compton D. R., Little P. J., Martin T. J., Beardsley P. M. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. Rapaka R. S., Makriyannis A. Structure-Activity Relationships of Cannabinoids. 1987;108-122 U.S. Govt. Printing Office, Washington.
34. Pertwee R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
35. Mechoulam R., Feigenbaum J. J., Lander N., Segal M., Järbe T. U. C., Hiltunen A. J., Consroe P. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 44:1988;762-764.
36. 8. Pharmacol. Biochem. Behav. 32:1989;661-666.
37. Melvin L. S., Johnson M. R., Harbert C. A., Milne G. M., Weissman A. A cannabinoid derived prototypical analgesic. J. Med. Chem. 27:1984;67-71.
38. Compton D. R., Johnson M. R., Melvin L. S., Martin B. R. Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260:1992;201-209.
39. Johnson M. R., Melvin L. S. The discovery of nonclassical cannabinoid analgetics. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;121-144 CRC Press, Boca Raton.
40. Melvin L., Milne G., Johnson M., Subramaniam B., Wilken G., Howlett A. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44:1993;1008-1015.
41. Martin B. R., Compton D. R., Thomas B. F., Prescott W. R., Little P. J., Razdan R. K., Johnson M. R., Melvin L. S., Mechoulam R., Ward S. J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
42. Devane W. A., Breuer A., Sheskin T., Järbe T. U. C., Eisen M. S., Mechoulam R. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:1992;2065-2069.
43. Howlett A. C., Johnson M. R., Melvin L. S., Milne G. M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297-302.
44. Ward S. J., Baizman E., Bell M., Childers S., D'Ambra T., Eissenstat M., Estep K., Haycock D., Howlett A., Luttinger D., Miller M. Aminoalkylindoles (AAIs): A new route to the cannabinoid receptor. Harris L. S. Problems of Drug Dependence 1990: Proceedings of the 52nd Annual Scientific Meeting. 1991;425-426 U.S. Govt. Printing Office, Washington.
45. 9. J. Pharmacol. Exp. Ther. 263:1992;1118-1126.
46. Eissenstat M. A., Bell M. R., D'Ambra T. E., Alexander E. J., Daum S., Ackerman J., Gruett M., Kumar V., Estep K. G., Olefirowicz E. M., Wetzel J., Alexander M. D., Weaver J., Haycock D., Luttinger D., Casiano F., Chippari S., Kuster J., Stevenson J., Ward S. J. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 38:1995;3094-3105.
47. Huffman J. W., Dai D., Martin B. R., Compton D. R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 4:1994;563-566.
48. Lainton J. A. H., Huffman J. W., Martin B. R., Compton D. R. 1-Alkyl-3-(1-naphthoyl)pyrroles: A new cannabinoid class. Tetrahedron Lett. 36:1995;1401-1404.
49. Bell M. R., D'Ambra T. E., Kumar V., Eissenstat M. A., Herrmann J. L., Wetzel J. R., Rosi D., Philion R. E., Daum S. J., Hlasta D. J., Kullnig R. K., Ackerman J. H., Haubrich D. R., Luttinger D. A., Baizman E. R., Miller M. S., Ward S. J. Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 34:1991;1099-1110.
50. Lichtman A. H., Smith P. B., Martin B. R. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain. 51:1992;19-26.
51. Compton D. R., Rice K. C., De Costa B. R., Razdan R. K., Melvin L. S., Johnson M. R., Martin B. R. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:1993;218-226.
52. 8. Tetrahydron. 53:1997;1557-1576.
53. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
54. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
55. 9. J. Pharmacol. Exp. Ther. 255:1990;624-635.
56. Pacheco M., Childers S. R., Arnold R., Casiano F., Ward S. J. Aminoalkylindoles: Actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257:1991;170-183.
57. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Cogny C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J. C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
58. 9. J. Pharmacol. Exp. Ther. 277:1996;586-594.
59. Lichtman A. H., Martin B. R. The selective cannabinoid antagonist, SR 141716A, blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav. 57:1997;7-12.
60. Edsall S. A., Knapp R. J., Vanderah T. W., Roeske W. R., Consroe P., Yamamura H. I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport. 7:1996;593-596.
61. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
62. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., Gopher A., Almog S., Martin B., Compton D., Pertwee R., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
63. Shohami E., Weidenfeld J., Ovadia H., Vogel Z., Hanus L., Fride E., Breuer A., Ben-Shabat S., Sheskin T., Mechoulam R. Endogenous and synthetic cannabinoids recent advances. CNS Drug Rev. 2:1996;429-451.
64. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
65. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
66. Stein E. A., Fuller S. A., Edgemond W. S., Campbell W. B. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br. J. Pharmacol. 119:1996;107-114.
67. Deutsch D. G., Chin S. A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
68. Willoughby K. A., Moore S. F., Martin B. R., Ellis E. F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
69. Barg J., Fride E., Hanus L., Levy R., Matus-Leibovitch N., Heldman E., Bayewitch M., Mechoulam R., Vogel Z. Cannabimimetic behavioral effects and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:1995;145-152.
70. Welch S. P. Blockade of cannabinoid-induced antinociception bynor. J. Pharmacol. Exp. Ther. 256:1993;633-640.
71. Reche I., Fuentes J. A., Ruiz-Gayo M. A role for central cannabinoid and opioid systems in peripheral Δ9-tetrahydrocannabinol-induced analgesia in mice. Eur. J. Pharmacol. 301:1996;75-81.
72. 99. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
73. Adams I. B., Compton D. R., Martin B. R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 1998.
74. Adams I. B., Ryan W., Singer M., Thomas B. F., Compton D. R., Razdan R. K., Martin B. R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
75. 9. Brain Res. 697:1995;83-90.
76. Martin W. J., Patrick S. L., Coffin P. O., Tsou K., Walker J. M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56:1995;2103-2109.
77. Basbaum A. I., Fields H. L. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7:1984;309-338.
78. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
79. Richardson J. D., Aanonsen L., Hargreaves K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
80. Landsman R. S., Burkey T. H., Consroe P., Roeske W. R., Yamamura H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 331:1997;R1-R2.
81. Price D. D., Dubner R. Neurons that subserve the sensory-discriminative aspects of pain. Pain. 4:1977;307-338.
82. Hohmann A., Martin W. J., Tsou K., Walker J. M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid win 55,212-2. Life Sci. 56:1995;2111-2118.
83. Martin W. J., Hohmann A. G., Walker J. M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
84. Yaksh T. L., Rudy T. A. Studies on the direct spinal action of narcotics in the production of analgesia in the rat. J. Pharmacol. Exp. Ther. 202:1977;411-428.
85. Yaksh T. L. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in periaqueductal gray. Brain Res. 160:1979;180-185.
86. Lichtman A. H., Martin B. R. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
87. 9. Brain Res. 578:1992;8-12.
88. Yaksh T. L. The antinociceptive effects of intrathecally-administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;3345-3405.
89. Tang A. H., Schoenfeld M. J. Comparison of subcutaneous and spinal subarachnoid injections of morphine and naloxone on analgesic tests in the rat. Eur. J. Pharmacol. 52:1978;215-223.
90. Martin W. J., Lai N. K., Patrick S. L., Tsou K., Walker J. M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:1993;300-304.
91. Jensen T. S., Yaksh T. L. Spinal monoamine and opiate systems partly mediate the antinociceptive effects produced by glutamate at brainstem sites. Brain Res. 321:1984;287-297.
92. Yaksh T. L., Yeung J. C., Rudy T. A. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: Observation of differential effects within the periqueductal gray. Brain Res. 114:1976;83-103.
93. Mayer D. J., Liebeskind J. C. Pain reduction by focal electrical stimulation of the brain: An anatomical and behavioral analysis. Brain Res. 68:1974;73-93.
94. Lichtman A. H., Dimen K. R., Martin B. R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology. 119:1995;282-290.
95. Barbaro N. M., Hammond D. L., Fields H. L. Effects of intrathecally administered methysergide and yohimbine on microstimulation-produced antinociception in the rat. Brain Res. 343:1985;223-229.
96. Jacob J. J., Ramabadran K., Campos-Medeiros M. A pharmacological analysis of levonantradol antinociception in mice. J. Clin. Pharmacol. 21:1981;327S-333S.
97. Ferri S., Cavicchini E., Romualdi P., Speroni E., Murari G. Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract ofCannabis sativa. Psychopharmacology. 89:1986;244-247.
98. Welch S. P., Thomas C., Patrick G. S. Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
99. Pugh G., Abood M. E., Welch S. P. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res. 689:1995;157-158.
100. Welch S. P., Stevens D. L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.
101. 9. J. Pharmacol. Exp. Ther. 279:1996;608-616.
102. Pugh J. G., Mason J. D. J., Combs V., Welch S. P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
103. Milstein S. L., MacCannell K., Karr G., Clark S. Marijuana-produced changes in pain tolerance: experienced and nonexperienced subjects. Int. Pharmacopsychiat. (Basel). 10:1975;177-182.
104. Bicher H. J., Mechoulam R. Pharmacological effects of two active constituents of marijuana. Arch. Int. Pharmacodyn. 172:1968;24-31.
105. Dewey W. L., Harris L. S., Kennedy J. S. Some pharmacological and toxicological effects of 1-transtrans. Arch. Int. Pharmacodyn. Ther. 196:1972;133-145.
106. Sofia R. D., Vassar H. B., Knobloch L. C. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacol. 40:1975;285-295.
107. Chesher G. B., Dahl C. J., Everingham M., Jackson D. M., Merchant-Williams H., Starmer G. A. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br. J. Pharmacol. 49:1973;588-594.
108. Wilson R. S., May E. L. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18:1975;700-703.
109. 9. Pharmacology. 27:1983;223-236.
110. 9. Psychopharmacology. 57:1978;243-248.
111. Bensemana D., Gascon A. L. Relationship between analgesia and turnover of brain biogenic amines. Can. J. Physiol. Pharmacol. 56:1978;721-730.
112. 9. Br. J. Anaesth. 55:1983;997-1000.
113. 9. Int. J. Clin. Pharmacol. Ther. Toxicol. 7:1973;75-81.
114. 9. Psychopharmacology. 35:1974;123-128.
115. Gilbert P. E. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J. Clin. Pharmacol. 21:1981;311S-319S.
116. Scheckel C. L., Boff E., Dahlen P., Smart T. Behavioral effects in monkeys of racemates of two biologically active marijuana constituents. Science. 160:1968;1467-1469.
117. Shaofen X., Xiaoding C., Wanying M., Zhenbang X., Yinying P. Effect of combination of drugs with acupuncture on analgesic efficacy. Acupuncture Electrother. Res. Int. J. 14:1989;103-113.
118. Yan G., Yin D., Khanolkar A. D., Compton D. R., Martin B. R., Makriyannis A. Synthesis and pharmacological properties of 11-hydroxy-3-(1′,1′-dimethylheptyl)hexahydrocannabinol: A high-affinity cannabinoid agonist. J. Med. Chem. 37:1994;2619-2622.
119. 8. Eur. J. Med. Chem. 24:1989;293-298.
120. 8. J. Med. Chem. 33:1990;1437-1443.
121. 899,11. J. Med. Chem. 34:1990;3310-3316.
122. 9. Pharmacol. Biochem. Behav. 40:1991;509-512.
123. Martin B. R., Compton D. R., Prescott W. R., Barrett R. L., Razdan R. K. Pharmacological evaluation of dimethylheptyl analogs of Δ9-THC: Reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alc. Depend. 37:1995;231-240.
124. 89. Pharmacol. Biochem. Behav. 46:1993;295-301.
125. 89. Life Sci. 56:1995;2013-2020.
126. Huffman J., Yu S., Showalter V., Abood M., Wiley J., Compton D., Martin B., Bramblett R., Reggio P. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 39:1996;3875-3877.
127. Seltzman H. H., Fleming D. N., Thomas B. F., Gilliam A. F., McCallion D. S., Pertwee R. G., Compton D. R., Martin B. R. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J. Med. Chem. 40:1997;3626-3634.
128. Ryan W., Banner K. W., Wiley J. L., Martin B. R., Razdan R. K. Potent anandamide analogs: The effect of changing the length and branching of the end pentyl chain. J. Med. Chem. 40:1997;3617-3625.
129. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogeneous cannabinoids. Nature. 394:1998;277-281.
130. Jaggar S. I., Hasnie F. S., Sellaturay S., Rice A. S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
131. Richardson J. D., Kilo S., Hargreaves K. M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119.